These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25511547)

  • 1. The use of interferon in melanoma patients: a systematic review.
    Di Trolio R; Simeone E; Di Lorenzo G; Buonerba C; Ascierto PA
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):203-12. PubMed ID: 25511547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon.
    Ascierto PA; Chiarion-Sileni V; Muggiano A; Mandalà M; Pimpinelli N; Del Vecchio M; Rinaldi G; Simeone E; Queirolo P
    J Chemother; 2014 Aug; 26(4):193-201. PubMed ID: 24621162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of interferons in the therapy of melanoma.
    Kirkwood JM; Ernstoff MS
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):180S-184S. PubMed ID: 1701805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons in melanoma.
    Agarwala SS; Kirkwood JM
    Curr Opin Oncol; 1996 Mar; 8(2):167-74. PubMed ID: 8727310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
    Eggermont AM
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):563-9. PubMed ID: 12382524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline.
    Petrella T; Verma S; Spithoff K; Quirt I; McCready D;
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):413-23. PubMed ID: 22245520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
    J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy of melanoma with interferon: lessons of the past decade.
    Ascierto PA; Kirkwood JM
    J Transl Med; 2008 Oct; 6():62. PubMed ID: 18954464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
    Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
    Fluck M; Kamanabrou D; Lippold A; Reitz M; Atzpodien J
    Cancer Biother Radiopharm; 2005 Jun; 20(3):280-9. PubMed ID: 15989473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunologic basis of interferon therapy in melanoma.
    Tarhini AA; Kirkwood JM
    Ann N Y Acad Sci; 2009 Dec; 1182():47-57. PubMed ID: 20074274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.